Sun Chenyu, Chen Yue, Hu Lei, Wu Yile, Liang Mingming, Ayaz Ahmed Mubashir, Bhan Chandur, Guo Zhichun, Yang Hongru, Zuo Yijing, Yan Yue, Zhou Qin
Internal Medicine, AMITA Health Saint Joseph Hospital Chicago, 2900 N. Lake Shore Drive, Chicago, IL, 60657, USA.
Department of Clinical Medicine, School of the First Clinical Medicine, Anhui Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, People's Republic of China.
Dig Dis Sci. 2021 Nov;66(11):3929-3937. doi: 10.1007/s10620-021-06872-z. Epub 2021 Feb 24.
Famotidine was reported to potentially provide benefits to Coronavirus Disease 2019 (COVID-19) patients. However, it remains controversial whether it is effective in treating COVID-19.
This study aimed to explore whether famotidine use is associated with reduced risk of the severity, death, and intubation for COVID-19 patients.
This study was registered on International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42020213536). A comprehensive search was performed to identify relevant studies up to October 2020. I-squared statistic and Q-test were utilized to assess the heterogeneity. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated through the random effects or fixed effects model according to the heterogeneity. Subgroup analyses, sensitivity analysis, and publication bias assessment were also conducted.
Five studies including 36,635 subjects were included. We found that famotidine use was associated with a statistically non-significant reduced risk of progression to severe disease, death, and intubation for Coronavirus Disease 2019 (COVID-19) patients (pooled RR was 0.82, 95% CI = 0.52-1.30, P = 0.40).
Famotidine has no significant protective effect in reducing the risk of developing serious illness, death, and intubation for COVID-19 patients. More original studies are needed to further clarify whether it is associated with reduced risk of the severity, death, and intubation for COVID-19 patients.
据报道，法莫替丁可能对2019冠状病毒病（COVID-19）患者有益。然而，其对COVID-19的治疗效果仍存在争议。
本研究旨在探讨使用法莫替丁是否与降低COVID-19患者病情严重程度、死亡和插管风险相关。
本研究在国际前瞻性系统评价注册库（PROSPERO）（注册号：CRD42020213536）上进行了注册。进行了全面检索以识别截至2020年10月的相关研究。采用I²统计量和Q检验评估异质性。根据异质性通过随机效应或固定效应模型计算合并风险比（RR）和95%置信区间（CI）。还进行了亚组分析、敏感性分析和发表偏倚评估。
纳入了五项研究，共36,635名受试者。我们发现，使用法莫替丁与2019冠状病毒病（COVID-19）患者病情进展至重症、死亡和插管风险的降低无统计学意义（合并RR为0.82，95%CI = 0.52 - 1.30，P = 0.40）。
法莫替丁在降低COVID-19患者发生重症、死亡和插管风险方面无显著保护作用。需要更多的原始研究来进一步阐明其是否与降低COVID-19患者病情严重程度、死亡和插管风险相关。
